Get the Stockscreener App
17.69
2.86%
-0.52
Crescent Biopharma Inc stock is traded at $17.69, with a volume of 119.47K.
It is down -2.86% in the last 24 hours and down -4.64% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$18.21
Open:
$18.39
24h Volume:
119.47K
Relative Volume:
0.44
Market Cap:
$487.80M
Revenue:
$11.88M
Net Income/Loss:
$-162.08M
P/E Ratio:
-1.417
EPS:
-12.484
Net Cash Flow:
$-156.43M
1W Performance:
-3.54%
1M Performance:
-4.64%
6M Performance:
+44.76%
1Y Performance:
+21.00%
1-Day Range:
$17.21
$18.39
1-Week Range:
$17.14
$19.05
52-Week Range:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
17.69 | 487.80M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Jan-21-26 | Initiated | Guggenheim | Buy |
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Announces Grants of Inducement Awards | Associated Press | syndication news - Enidnews.com
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CBIO: CR-001 and ADC pipeline aim for best-in-class oncology therapies, with pivotal data expected from 2027 - TradingView
Crescent Biopharma (CBIO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
HC Wainwright & Co. Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
CBIO Q1 2026 Earnings: Exceeding EPS Estimates Despite Net LossSubscription Growth Report - newsline.com
[Form 4] CRESCENT BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Crescent Biopharma (CBIO) director receives grant of 11,050 stock options at $17.01 - Stock Titan
Crescent Biopharma director granted 11,050 options | CBIO Insider Trading - Stock Titan
Director at Crescent Biopharma (CBIO) receives option grant for 11,050 shares - Stock Titan
Fairmount-linked director awarded 11,050 CBIO options at $17.01 exercise price - Stock Titan
Crescent Biopharma shareholders back directors, pay and auditor - TipRanks
Crescent Biopharma (CBIO) investors back directors, auditor and annual say-on-pay - Stock Titan
Crescent Biopharma, Inc. to Present at Jefferies and Goldman Sachs Healthcare Conferences in June 2026 - Quiver Quantitative
Crescent Biopharma to Present at June Investor Conferences - GlobeNewswire
CBIO: Directors elected, auditor ratified, and executive compensation approved with annual advisory votes - TradingView
CBIO: All proposals, including director elections and auditor ratification, were approved - TradingView
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Crescent Biopharma (CBIO) and Erasca (ERAS) - The Globe and Mail
Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Crescent Biopharma Rings the Closing Bell - Nasdaq
Crescent Biopharma downgraded by H.C. Wainwright - Quantisnow
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral By Investing.com - Investing.com South Africa
H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral - Investing.com
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Decline Risk - newsline.com
Crescent Biopharma (CBIO) Edges Lower, Holds Near Key Support LevelBlock Trade Flow - The Legal Advocate
CBIO Q1 2026 Earnings: EPS Beat on Lower Net Loss as Pipeline AdvancesEarnings Forecast Report - newsline.com
Crescent Biopharma (CBIO) Surges 4.59% as Biotech Sector Gains MomentumWMA Signal - The Legal Advocate
Crescent Biopharma (CBIO) Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Edge LowerFree Cash Flow Trends - The Legal Advocate
CBIO Q1 2026 Earnings: Narrowed Loss Beat Estimates as Clinical Pipeline AdvancesDownward Estimate Revision - newsline.com
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
Crescent Biopharma (CBIO) Surges 5.3% as Bullish Momentum BuildsInstitutional Flow Picks - newsline.com
CBIO: Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions - TradingView
CBIO Q1 2026 Earnings: Narrower Loss Surprises, Pipeline Progress ContinuesDividend Growth Analysis - Newser
Crescent Biopharma Inc. (CBIO) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineDividend Cut Risk - Newser
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Sahm
CBIO Q1 2026 Earnings: Narrowed Loss Beats Estimates as Clinical Pipeline ProgressesSegment Revenue Breakdown - The Legal Advocate
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Crescent Biopharma to present CR-001 trial data at ASCO meeting - Investing.com Nigeria
Crescent Biopharma to present CR-001 trial data at ASCO meeting By Investing.com - Investing.com South Africa
Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027 - Quiver Quantitative
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 ... - Caledonian Record
Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan
Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO) - Stock Titan
New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - 富途牛牛
Balyasny entities disclose 1.51M shares in Crescent Biopharma (CBIO) - Stock Titan
Crescent Biopharma gives 5 new hires options on 129,075 shares - Stock Titan
Number of shareholders of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):